Chiasma Inc (CHMA)

3.76  -0.24 (-6%)

After market: 3.78 +0.02 (+0.53%)

Fundamental Rating

2

CHMA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. The financial health of CHMA is average, but there are quite some concerns on its profitability. CHMA has a expensive valuation and it also scores bad on growth.



0

1. Profitability

1.1 Basic Checks

CHMA had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -56.38%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -2408.65%
PM (TTM) -2968.35%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

There is no outstanding debt for CHMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.09, we must say that CHMA is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for CHMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.09
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 7.91 indicates that CHMA has no problem at all paying its short term obligations.
CHMA has a Quick Ratio of 7.08. This indicates that CHMA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 7.91
Quick Ratio 7.08

3

3. Growth

3.1 Past

CHMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -46.36%.
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-36.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

CHMA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.36% yearly.
Based on estimates for the next years, CHMA will show a very strong growth in Revenue. The Revenue will grow by 280.08% on average per year.
EPS Next Y12.13%
EPS Next 2Y22.91%
EPS Next 3Y28.31%
EPS Next 5Y15.36%
Revenue Next Year1731.35%
Revenue Next 2Y702.55%
Revenue Next 3Y405.04%
Revenue Next 5Y280.08%

3.3 Evolution

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHMA. In the last year negative earnings were reported.
Also next year CHMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -1.42

4.3 Compensation for Growth

A more expensive valuation may be justified as CHMA's earnings are expected to grow with 28.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.91%
EPS Next 3Y28.31%

0

5. Dividend

5.1 Amount

No dividends for CHMA!.
Industry RankSector Rank
Dividend Yield N/A

Chiasma Inc

NASDAQ:CHMA (8/5/2021, 7:18:03 PM)

After market: 3.78 +0.02 (+0.53%)

3.76

-0.24 (-6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap217.68M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.38%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -2408.65%
PM (TTM) -2968.35%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.91
Quick Ratio 7.08
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-46.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y12.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y